Fabry disease (Anderson-Fabry disease) is an X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (α-Gal A), leading to accumulation of globotriaosylceramide (Gb3/GL-3) in various tissues throughout the body. The disease affects multiple organ systems including the kidneys, heart, nervous system, and skin. Treatment strategies for Fabry disease have evolved significantly over the past two decades, now encompassing disease-specific therapies, symptomatic management, and emerging approaches.
Enzyme replacement therapy remains the cornerstone of Fabry disease treatment, providing exogenous α-Gal A to reduce substrate accumulation.
- Manufacturer: Takeda (formerly Shire)
- Dose: 0.2 mg/kg body weight every other week via intravenous infusion
- Infusion time: Approximately 40 minutes
- Efficacy: Demonstrated reduction in Gb3 accumulation in renal podocytes, endothelial cells, and myocardial cells; stabilization of renal function; reduction in cardiac mass; improvement in neuropathic pain and quality of life
- Immunogenicity: Approximately 50-70% of patients develop anti-drug antibodies, which may reduce efficacy in some patients
- Manufacturer: Sanofi Genzyme
- Dose: 1 mg/kg body weight every other week via intravenous infusion
- Infusion time: Approximately 1-2 hours
- Efficacy: Similar to agalsidase alfa in reducing substrate burden and stabilizing organ function; approved for patients with confirmed Fabry disease
- Immunogenicity: Similar antibody development rates as agalsidase alfa
Both ERT formulations have demonstrated similar clinical outcomes in head-to-head comparisons. The choice between formulations may depend on:
- Payer coverage and reimbursement
- Infusion tolerability
- Antibody status
- Patient preference for infusion duration
- Manufacturer: Amicus Therapeutics
- Mechanism: Oral small-molecule pharmacological chaperone that binds to and stabilizes mutant α-Gal A, facilitating proper folding and trafficking to lysosomes
- Dose: 123 mg every other day (on alternate days)
- Eligibility: Patients with amenable GLA gene mutations (approximately 35-50% of all Fabry patients)
- Efficacy: Demonstrated reduction in Gb3 in kidney interstitial capillaries; stabilization of renal function; reduction in cardiac mass; improvement in neuropathic pain
- Advantages: Oral administration; no risk of infusion reactions; no immunogenicity concerns
- Limitations: Only effective for patients with amenable mutations; requires genetic testing to confirm eligibility
Gene therapy approaches for Fabry disease aim to deliver a functional GLA gene to restore endogenous α-Gal A production. Several clinical trials are ongoing:
- AAV-mediated gene delivery: Early-phase trials showing promising results with sustained α-Gal A expression
- lentiviral-based ex vivo gene therapy: Autologous hematopoietic stem cell transduction
- Current status: Phase I/II trials ongoing; long-term safety and efficacy data pending
Research into substrate reduction therapy aims to reduce the production of Gb3 substrate rather than increasing its catabolism:
- Lucerastat (NCT03425539): Oral glucosylceramide synthase inhibitor; completed Phase III trials but did not meet primary endpoint
- Venglustat (NCT02446211): Similar approach; development discontinued for Fabry disease
- Pegunigalsidase alfa (PRX-102): Pegylated form of α-Gal A with extended half-life
- Dose: 2 mg/kg every 4 weeks
- Phase III trials completed; demonstrates potential for less frequent dosing
Painful peripheral neuropathy is a hallmark of Fabry disease, resulting from small-fiber neuropathy due to Gb3 accumulation.
- Gabapentin: 900-2400 mg/day in divided doses
- Pregabalin: 150-600 mg/day in divided doses
- Carbamazepine: 200-1200 mg/day in divided doses (may exacerbate cardiac conduction issues)
- Opioids: For severe, refractory pain (use with caution due to addiction potential)
- Topical therapies: Capsaicin cream, lidocaine patches
- Non-pharmacological: Physical therapy, acupuncture, cognitive behavioral therapy
- ACE inhibitors (e.g., lisinopril, enalapril): First-line for proteinuria reduction
- ARBs (e.g., losartan, valsartan): Alternative or adjunct to ACE inhibitors
- Target: Reduce proteinuria to <0.5 g/day when possible
- Hemodialysis: Required when eGFR falls below 15 mL/min/1.73m²
- Peritoneal dialysis: Alternative option
- Renal transplantation: Effective in patients with end-stage renal disease; Gb3 accumulation may continue in other organs
- Antiarrhythmic medications: Amiodarone, sotalol for ventricular arrhythmias
- Pacemaker implantation: For patients with conduction abnormalities
- ICD implantation: For secondary prevention of sudden cardiac death in high-risk patients
- Standard heart failure regimens: ACE inhibitors, ARBs, beta-blockers, diuretics
- Caution: Some standard heart failure medications may not be well-tolerated in Fabry cardiomyopathy
- Annual echocardiogram
- Annual cardiac MRI with late gadolinium enhancement
- Regular ECG and Holter monitoring
- Antiplatelet therapy: Low-dose aspirin or clopidogrel for stroke prevention
- Blood pressure control: Tight management of hypertension
- Statins: Consider for cardiovascular risk reduction
- ** anticoagulation**: Warfarin or DOACs for patients with atrial fibrillation
- Angiokeratoma: Laser therapy, cryotherapy for symptomatic lesions
- Hypohidrosis: Skin moisturizers, environmental temperature control
- Telangiectasias: Laser therapy if symptomatic
- Nausea/vomiting: Metoclopramide, ondansetron
- Diarrhea: Loperamide, clonidine
- Constipation: Fiber supplements, laxatives
- Early satiety: Small, frequent meals; prokinetic agents
¶ Monitoring and Assessment
- Genetic testing: Confirm GLA mutation and identify amenable mutations for migalastat
- Enzyme activity: α-Gal A activity in plasma or leukocytes
- Biomarkers: Lyso-Gb3 (globotriaosylsphingosine) level
- Organ assessment:
- Renal: eGFR, proteinuria, kidney biopsy
- Cardiac: ECG, echocardiogram, cardiac MRI
- Neurological: Brain MRI, nerve conduction studies
- Ophthalmological: Slit-lamp examination
| Parameter |
Frequency |
| eGFR |
Every 6-12 months |
| Proteinuria |
Every 6-12 months |
| Cardiac MRI |
Every 2-3 years |
| Echocardiogram |
Annually |
| ECG/Holter |
Annually |
| Lyso-Gb3 |
Every 1-2 years |
| Neurological assessment |
Annually |
- Lyso-Gb3 reduction: Reflects substrate clearance
- Renal function stabilization: Stable eGFR trajectory
- Cardiac mass reduction: Decreased left ventricular mass index
- Pain score improvement: Reduced neuropathic pain severity
- Quality of life: Patient-reported outcomes
- ERT is approved for patients as young as 8 years (agalsidase beta) or 16 years (agalsidase alfa in Europe)
- Migalastat approved for patients ≥12 years with amenable mutations
- Dosing based on body weight
- Careful monitoring of growth and development
¶ Pregnancy and Breastfeeding
- Pregnancy: ERT continuation generally recommended to prevent disease progression; discuss risks and benefits
- Breastfeeding: Limited data; ERT not recommended during breastfeeding
- Family planning: Genetic counseling important for affected females
- Many females are symptomatic and require treatment
- Treatment decisions based on phenotype rather than genotype alone
- May have milder disease course but significant variability